ProMIS Neurosciences, Inc. (PMN)
NASDAQ: PMN · Real-Time Price · USD
13.30
-0.71 (-5.07%)
Jul 16, 2026, 4:00 PM EDT - Market closed
ProMIS Neurosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
11
Market Cap
119.27M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Fortress Biotech | 66.16M |
| Spero Therapeutics | 61.19M |
| Cue Biopharma | 32.73M |
| Seer, Inc. | 15.17M |
| Coya Therapeutics | 7.94M |
| Genelux | 8.00K |
| Fractyl Health | 3.00K |
PMN News
- 2 days ago - ProMIS Neurosciences reports amyloid-beta oligomer reduction by PMN310 - TheFly
- 3 days ago - ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026 - GlobeNewsWire
- 8 days ago - ProMIS Neurosciences initiated with a Buy at Roth Capital - TheFly
- 9 days ago - ProMIS Neurosciences initiated with a Buy at Roth Capital - TheFly
- 16 days ago - ProMIS Neurosciences initiated with an Overweight at Cantor Fitzgerald - TheFly
- 6 weeks ago - ProMIS Neurosciences Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 7 weeks ago - ProMIS Neurosciences to Participate in Upcoming Conferences in June - GlobeNewsWire
- 2 months ago - ProMIS Neurosciences Transcript: AGM 2026 - Transcripts